Clinical trials: Small Cell Carcinoma of the Ovary Hypercalcemic Type
Small Cell Ovarian Carcinoma
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to…
- Trial name
- PembroSCCOHT (NCT04602377)
- Testing
- Pembrolizumab 25 MG/ML [Keytruda]
- Where
- 13 sites in France
- Volunteers
- 27 people
- Sponsor
- ARCAGY/ GINECO GROUP
Small Cell Carcinoma, Hypercalcaemic Type, Ovarian Cancer
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
- Trial name
- Pemb-HT (NCT05368207)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.